-
公开(公告)号:US12110263B2
公开(公告)日:2024-10-08
申请号:US17740260
申请日:2022-05-09
申请人: CORTEXYME, INC.
发明人: Andrei W. Konradi , Robert A. Galemmo, Jr. , Stephen S. Dominy , Casey C. Lynch , Leslie J. Holsinger
IPC分类号: C07C233/62 , A61K31/165 , A61K31/167 , A61K31/41 , A61K31/42 , A61K31/44 , A61K31/4402 , A61K31/4406 , A61K31/4409 , A61K31/4439 , A61K31/505 , A61K31/513 , A61K31/655 , A61K45/06 , A61P25/00 , A61P31/04 , C07B59/00 , C07C233/78 , C07C235/10 , C07C235/50 , C07C237/42 , C07C245/08 , C07C247/16 , C07C247/18 , C07C317/28 , C07C323/40 , C07C323/42 , C07C381/00 , C07D213/65 , C07D213/68 , C07D213/70 , C07D213/81 , C07D213/82 , C07D239/34 , C07D239/36 , C07D239/38 , C07D257/04 , C07D261/12 , C07D401/12 , C07D413/12 , C07F5/02
CPC分类号: C07C233/62 , A61K31/165 , A61K31/167 , A61K31/41 , A61K31/42 , A61K31/44 , A61K31/4402 , A61K31/4406 , A61K31/4409 , A61K31/4439 , A61K31/505 , A61K31/513 , A61K31/655 , A61K45/06 , A61P25/00 , A61P31/04 , C07B59/001 , C07C233/78 , C07C235/10 , C07C235/50 , C07C237/42 , C07C245/08 , C07C247/16 , C07C247/18 , C07C317/28 , C07C323/40 , C07C323/42 , C07C381/00 , C07D213/65 , C07D213/68 , C07D213/70 , C07D213/81 , C07D213/82 , C07D239/34 , C07D239/36 , C07D239/38 , C07D257/04 , C07D261/12 , C07D401/12 , C07D413/12 , C07F5/02 , C07C2601/08
摘要: The present invention provides compounds according to Formula I as described herein, and their use for inhibiting the lysine gingipain protease (Kgp) from the bacterium Porphyromonas gingivalis. Also described are gingipain activity probe compounds and methods for assaying gingipain activity are also described, as well as methods for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease.
-
公开(公告)号:US20240252474A1
公开(公告)日:2024-08-01
申请号:US18421171
申请日:2024-01-24
发明人: Gloria LEE , Mireille GILLINGS
IPC分类号: A61K31/4406 , A61K39/00 , A61K39/395 , A61P35/00
CPC分类号: A61K31/4406 , A61K39/3955 , A61P35/00 , A61K2039/505 , A61K2039/545
摘要: Provided herein are methods comprising an HDAC inhibitor (HDACi), and/or a PD-L1 and/or a PD-1 inhibitor, and/or a CTLA-4 inhibitor, and/or an anti-cancer agent. Also, provided herein are pharmaceutical compositions suitable for treatment of cancer.
-
3.
公开(公告)号:US20240226177A1
公开(公告)日:2024-07-11
申请号:US18592478
申请日:2024-02-29
发明人: Weiyun Shi , Qingjun Zhou , Zongyi Li , Chunxiao Dong , Haoyun Duan
IPC分类号: A61K35/30 , A61K31/4406 , A61K31/4439 , A61P27/02 , C12N5/079
CPC分类号: A61K35/30 , A61K31/4406 , A61K31/4439 , A61P27/02 , C12N5/0621
摘要: Retinal pigment epithelial cells can be used for replacing corneal endothelial cells, preventing and treating diseases or symptoms such as corneal endothelial functional decompensation. The retinal pigment epithelial cell transplantation, e.g., to the anterior chamber of an eye of the subject, can restore corneal transparency, reduce corneal thickness, reconstruct corneal endothelial barrier function, effectively treat corneal endothelial functional decompensation and corneal endothelial dysfunction.
-
公开(公告)号:US12011432B2
公开(公告)日:2024-06-18
申请号:US17260998
申请日:2019-07-18
发明人: Chris Dealwis
IPC分类号: A61K31/404 , A61K31/15 , A61K31/341 , A61K31/381 , A61K31/426 , A61K31/4406 , A61K31/4412 , A61K31/52 , A61K45/06 , A61P35/00
CPC分类号: A61K31/404 , A61K31/15 , A61K31/341 , A61K31/381 , A61K31/426 , A61K31/4406 , A61K31/4412 , A61K31/52 , A61K45/06 , A61P35/00
摘要: A method of modulating ribonucleotide reductase activity in a neoplastic cell includes administering to the cell an amount of a hydrazone or hydrazine ribonucleotide reductase modulator (RRmod), the amount being effective to inhibit neoplastic cell growth.
-
公开(公告)号:US20240041849A1
公开(公告)日:2024-02-08
申请号:US18478261
申请日:2023-09-29
IPC分类号: A61K31/4406 , A61P25/08 , A61K31/136 , A61K31/18
CPC分类号: A61K31/4406 , A61P25/08 , A61K31/136 , A61K31/18
摘要: Compounds and methods are provided for the treatment of neurological or mitochondrial diseases, including epilepsy. In some embodiments, the compounds are substituted 1,4-naphthoquinones.
-
公开(公告)号:US20240024266A1
公开(公告)日:2024-01-25
申请号:US18036998
申请日:2021-11-16
发明人: Tomoichiro Asano , Takemasa Sakaguchi , Takeshi Yamamotoya , Yusuke Nakatsu , Hisanaka Ito , Takayoshi Okabe , Jeffrey Encinas
IPC分类号: A61K31/196 , A61P31/14 , A61K31/47 , A61K31/403 , A61K31/357 , A61K31/198 , A61K31/216 , A61K31/538 , A61K31/235 , A61K31/341 , A61K31/405 , A61K31/4439 , A61K31/4709 , A61K31/498 , A61K31/4045 , A61K31/27 , A61K31/194 , A61K31/192 , A61K31/683 , A61K31/4035 , A61K31/197 , A61K31/36 , A61K31/4406 , A61K31/245 , A61K31/472 , A61K31/444
CPC分类号: A61K31/196 , A61P31/14 , A61K31/47 , A61K31/403 , A61K31/357 , A61K31/198 , A61K31/216 , A61K31/538 , A61K31/235 , A61K31/341 , A61K31/405 , A61K31/4439 , A61K31/4709 , A61K31/498 , A61K31/4045 , A61K31/27 , A61K31/194 , A61K31/192 , A61K31/683 , A61K31/4035 , A61K31/197 , A61K31/36 , A61K31/4406 , A61K31/245 , A61K31/472 , A61K31/444
摘要: [Problem] To develop novel therapeutic agents for viral diseases such as coronavirus infections.
[Solution] The present invention provides a therapeutic or prophylactic agent for viral diseases containing a compound with inhibitory activity against the function of Pin1 or a pharmaceutically acceptable salt thereof as an active ingredient.-
公开(公告)号:US20230414571A1
公开(公告)日:2023-12-28
申请号:US18466829
申请日:2023-09-14
申请人: SOOCHOW UNIVERSITY
发明人: Jian LIU , Rui SHI , Peichen PAN , Rui LV , Zhenhui KANG , Tingjun HOU
IPC分类号: A61K31/417 , A61K31/381 , A61K31/4402 , A61K31/165 , A61K31/166 , A61K31/4409 , A61K31/4406 , A61K31/137 , A61K31/505 , A61K31/496 , A61P35/00 , H01J49/16
CPC分类号: A61K31/417 , A61K31/381 , A61K31/4402 , A61K31/165 , A61K31/166 , A61K31/4409 , A61K31/4406 , A61K31/137 , A61K31/505 , A61K31/496 , A61P35/00 , H01J49/164
摘要: The present invention provides an application of a small-molecule compound in preparation of an antitumor drug. A series of small-molecule drugs with high brain tumor growth activity inhibitory properties are obtained, are docked to pharmacodynamic analysis of the small-molecule drugs, and do not need to be transferred to other testing platforms.
-
公开(公告)号:US11819554B2
公开(公告)日:2023-11-21
申请号:US15760765
申请日:2016-09-16
IPC分类号: A61K31/711 , A61K35/30 , A61K38/45 , A61K38/53 , A61K39/395 , A61K48/00 , A61K31/5377 , A61K31/549 , A61K31/706 , A61K31/713 , C12Q1/6883 , C12N15/113 , A61K31/7088 , A61K31/404 , A61K31/546 , A61K31/167 , A61K31/497 , A61K31/506 , A61K31/437 , A61K31/4406 , A61K31/522 , A61K31/496 , A61P25/14 , A61P15/02 , A61K31/7105
CPC分类号: A61K48/005 , A61K31/167 , A61K31/404 , A61K31/437 , A61K31/4406 , A61K31/496 , A61K31/497 , A61K31/506 , A61K31/522 , A61K31/5377 , A61K31/546 , A61K31/549 , A61K31/706 , A61K31/7088 , A61K31/711 , A61K31/713 , A61K31/7105 , A61K35/30 , A61K38/45 , A61K38/53 , A61K39/3955 , A61K48/0016 , A61P15/02 , A61P25/14 , C12N15/113 , C12Q1/6883 , C12N2310/11 , C12N2310/14 , C12N2310/141 , C12N2310/531 , C12Q2600/154 , C12Q2600/158 , C12Y201/01037 , C12Y201/01043 , C12Y603/02019
摘要: The disclosure relates to methods and compositions for reactivating a silenced FMR1 gene. In some aspects, methods described by the disclosure are useful for treating a FMR1-inactivation-associated disorder (e.g., fragile X syndrome).
-
9.
公开(公告)号:US11806337B2
公开(公告)日:2023-11-07
申请号:US17875216
申请日:2022-07-27
IPC分类号: A61K31/4409 , A61K31/196 , A61K31/245 , A61K31/415 , A61K31/4155 , A61K31/417 , A61K31/4192 , A61K31/42 , A61K31/422 , A61K31/426 , A61K31/427 , A61K31/4355 , A61K31/437 , A61K31/44 , A61K31/4402 , A61K31/4406 , A61K31/4418 , A61K31/443 , A61K31/4433 , A61K31/4436 , A61K31/4439 , A61K31/444 , A61K31/454 , A61K31/4545 , A61K31/47 , A61K31/472 , A61K31/4725 , A61K31/497 , A61K31/50 , A61K31/505 , A61K31/5377 , A61K31/5386 , C07C275/42 , C07D213/40 , C07D213/56 , C07D213/643 , C07D213/73 , C07D213/74 , C07D231/12 , C07D233/64 , C07D237/08 , C07D239/26 , C07D249/04 , C07D261/08 , C07D263/32 , C07D277/28 , C07D401/06 , C07D401/12 , C07D403/12 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/12 , C07D413/14 , C07D417/12 , C07D471/04 , C07D498/08
CPC分类号: A61K31/4409 , A61K31/196 , A61K31/245 , A61K31/415 , A61K31/417 , A61K31/4155 , A61K31/4192 , A61K31/42 , A61K31/422 , A61K31/426 , A61K31/427 , A61K31/437 , A61K31/4355 , A61K31/44 , A61K31/4402 , A61K31/443 , A61K31/444 , A61K31/4406 , A61K31/4418 , A61K31/4433 , A61K31/4436 , A61K31/4439 , A61K31/454 , A61K31/4545 , A61K31/47 , A61K31/472 , A61K31/4725 , A61K31/497 , A61K31/50 , A61K31/505 , A61K31/5377 , A61K31/5386 , C07C275/42 , C07D213/40 , C07D213/56 , C07D213/643 , C07D213/73 , C07D213/74 , C07D231/12 , C07D233/64 , C07D237/08 , C07D239/26 , C07D249/04 , C07D261/08 , C07D263/32 , C07D277/28 , C07D401/06 , C07D401/12 , C07D403/12 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/12 , C07D413/14 , C07D417/12 , C07D471/04 , C07D498/08
摘要: Provided herein are small molecule activators of Nicotinamide Phosphoribosyltransferase (NAMPT), compositions comprising the compounds, and methods of using the compounds and compositions.
-
10.
公开(公告)号:US20230346769A1
公开(公告)日:2023-11-02
申请号:US18004932
申请日:2021-07-09
发明人: Enrique Gargía-España Monsonís , María Paz Clares García , Estefanía Delgado Pinar , Clotilde Marín Sánchez , Manuel Sánchez Moreno , Rubén Martín Escolano , Álvaro Martín Montes
IPC分类号: A61K31/4406 , A61K31/4409 , A61P33/02 , A61K31/47 , A61K31/4402 , A61K45/06
CPC分类号: A61K31/47 , A61K31/4402 , A61K31/4406 , A61K31/4409 , A61K45/06 , A61P33/02
摘要: Use of simple acyclic polyamines for the treatment of parasites of the family Trypanosomatidae
The present invention provides the use of certain single acyclic polyamines of Formula (I), attached to heterocycles, for the treatment of leishmaniasis and trypanosomiasis. All the compounds studied show antiparasitic activity against Leishmania species, comparable or superior to that of the active ingredient of the drug commonly used to treat this disease, but with a macrophage toxicity similar to or, in most cases, lower than that of the commercial reference compound, and with higher selectivity indices against strains representative of the three clinical forms of the disease: cutaneous, mucocutaneous and visceral. The compounds show ability to inhibit parasite superoxide dismutase, generally at concentrations lower than those required to inhibit human superoxide dismutase. All this supports its usefulness for treating leishmaniasis and also trypanosomiasis.
-
-
-
-
-
-
-
-
-